About
Myosin Therapeutics develops first-in-class therapies that target molecular motor proteins, such as non-muscle myosin II, to treat oncology and central nervous system diseases including glioblastoma, and is currently enrolling patients for a Phase 1/2 clinical trial in glioblastoma.
Explore Myosin Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.